Botulinum neurotoxin (BoNT) is a major therapeutic agent. Of seven native BoNT serotypes (A to G), only A and B are currently used in the clinic. Here we compared the potency of commercially available purified native serotypes A1 to F1 across in vitro, ex vivo, and in vivo assays. BoNT potency in vitro was assessed in rat primary cells (target protein cleavage and neurotransmitter release assays) in supraspinal, spinal, and sensory systems. BoNT potency ex vivo was measured in the mouse phrenic nerve hemidiaphragm (PNHD) assay, measuring muscle contractility. In vivo, BoNT-induced muscle relaxation in mice and rats was assessed in the Digit Abduction Score (DAS) test, while effects on body weight (BW) gain were used to assess tolerability. In all assays, all BoNT serotypes were potent toxins, except serotype D1 in vivo which failed to produce significant muscle flaccidity in mice and rats. In rats, all serotypes were well-tolerated, whereas in mice, reductions in BW were detected at high doses. Serotype A1 was the most potent serotype across in vitro, ex vivo, and in vivo assays. The rank order of potency of the serotypes revealed differences among assays. For example, species-specificity was seen for serotype B1, and to a lesser extent for serotype C1. Serotypes F1 and C1, not currently in the clinic, showed preference for sensory over motor models and therefore could be considered for development in conditions involving the somatosensory system.
they contain motor neurons that are clinically relevant, DRG neurons are a sensory peripheral nervous system model, whereas CTX neurons represent a supraspinal model highly sensitive to BoNT intoxication. [12] [13] [14] [15] The cleavage of their protein substrate (soluble Nehtylmaleimide-sensitive factor attachment protein receptor, SNARE) and the resulting inhibition of neurotransmitter release can be assayed in primary neurons to provide a complementary in vitro readout of BoNT activity. The mouse phrenic nerve hemidiaphragm (PNHD) assay is an ex vivo assay for assessing the neuroparalytic activity of BoNTs, as it directly records the blockade of neuromuscular transmission. 16 In vivo, activity of BoNTs in the digit abduction score (DAS) test in mice and rats is indicative of their muscle-relaxant properties, whereas reductions in body weight (BW) gain are indicative of toxin spread and migration away from the injected site.
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| MATERIALS AND METHODS

| Botulinum toxins (BoNTs) and general reagents
In this study, commercially available, research grade, purified native botulinum neurotoxins A1, B1, C1, D1, E1, and F1 were studied, and they are referred as A to F throughout the manuscript for easiness.
BoNT serotypes A to F were purchased from Metabiologics Inc.
(Madison, WI) as purified toxins and their purity analyzed by SDS-PAGE (% of purity was as follows: 100% for serotype A, 89% serotype B, 87.6% serotype C, 37.3% serotype D, 54% serotype E, and 64.3% serotype F). Serotypes A, B, and E were also purchased from List Biological Laboratories Inc. (Campbell, CA) as complex toxins and BSA was added during the reconstitution step of the lyophilized powder supplied, as recommended by the manufacturer. The addition of BSA (final concentration 1 mg/mL of BSA to μg of BoNT) made analysis of purity by standard SDS-PAGE not reliable. Toxins were assayed as per manufacturers' stated quantities present in the vials, and no apparent differences were observed between toxins from the two suppliers. BoNT/E was treated with trypsin prior to its use. General laboratory reagents were from Sigma (Dorset, UK), unless otherwise specified.
| Animals
Sprague Dawley rats and CD-1 mice were chosen for this study as they are species and strains commonly used to study BoNT biology in models of primary neuronal cultures, the hemidiaphragm assay and the DAS assay 12, 15, 19, 21, 22 .
All animals for tissue donation were treated humanely and in accordance with Home Office guidelines, UK. Culling of the animals for tissue donation was performed by CO 2 involving animals. 23 For in vivo experiments adult male CD-1 mice (24-30 g) were purchased from Charles River (Saint-Germain-Nuelles, France), whereas adult female Sprague Dawley rats (170-200 g) were purchased from Janvier Labs (Saint Berthevin, France). Male mice are routinely used in our facilities. Regarding rats, BW gain is slower in females than in males and as such, they are easier to handle in experiments involving longitudinal testing. Therefore, for these studies we used male mice and female rats, as stated. Animals were group-housed in plastic cages and maintained on a 12-hours light/ dark cycle (lights on from 07:00 to 19:00 hours) under constant temperature (22 ± 2°C) and humidity (>45%) conditions. Animals had free access to water and were fed with pellet complete diet ad libitum. The diet, reference A04C-10, was sterilized by irradiation and controlled by SAFE food supplier (Augy, France). Mains tap water was filtered (0.2 μm) and UV (wave-length: 254 nm) sterilized and distributed in sterilizable plastic bottles equipped with stainless steel drinking tubes mounted in Bakelite/rubber and stainless-steel fittings.
The water supply was analyzed twice a year by the Paris water control center, PERMO (Paris, France) and was free of contaminants.
Animals were acclimatized for at least 7 days prior to experiments.
On the day of the experiment animals were anesthetized prior to
BoNT treatment using a mixture of 4% isoflurane/oxygen for mice, and of 3% isoflurane/oxygen for rats. Prior to BoNT treatment, both mice and rats were randomized to obtain homogenous average BW per group. Administration of BoNTs/vehicle and data collection was performed by an operator blind to treatment.
| SCN cell culture
SCN were prepared by the method described previously. 12 Eagle's medium (MEM) with glutamax supplemented with 5% fetal bovine serum (FBS), 5% horse serum, 0.6% glucose, and 0.15% sodium bicarbonate (all from Gibco). After 24 hours, a further 125 μL of the medium was changed to MEM with glutamax supplemented with 5% horse serum, 0.6% glucose, 0.15% sodium bicarbonate, N2 supplement (all from Gibco), 40 ng/mL corticosterone, and 20 ng/mL triiodothyronine (Sigma). Cultures were grown in a humidified 10% CO 2 atmosphere at 37°C. On day in vitro (DIV) 6 antimitotic compounds 5-fluoro-2′-deoxyuridine and uridine were added.
Cells were maintained by replacement of half the medium twice per week.
| DRG cell culture
DRG neurons were prepared by the method described previously. 15 Briefly, ganglia were dissected from embryonic day 15 (E15) Sprague
Dawley rat embryos and digested in trypsin/EDTA solution (Gibco) for 40 minutes at 37°C. The ganglia were then triturated to disaggregate the cells. Cells were plated at a density of 125 000 cells/well in 96-well plates coated with Matrigel in Dulbecco's modified Eagle's medium (containing 5% inactivated FBS, 2% B27 supplement (all from Gibco), 100 ng/mL 2.5 S mouse nerve growth factor (Promega, Southampton, UK), 5 mmol/L l-glutamine and 0.6% glucose. Cultures were grown in a humidified 5% CO 2 atmosphere at 37°C. On DIV 2 the antimitotic compound cytosine arabinoside (10 μmol/L, Sigma) was added to prevent growth of rapidly dividing glial and endothelial cells. Cells were maintained by replacement of half the medium twice per week.
| CTX cell culture
CTX were prepared from embryonic day 17-18 (E17-E18) Sprague
Dawley rat embryos, as described previously. 21 This provided confidence that the diaphragm muscle contraction was due to acetylcholine release from presynaptic neurons rather than direct electrical stimulation of the muscle through the buffer.
Tubocurarine was washed out, and following a further period of stability, the control contractile tension of the muscle was recorded before the assay buffer was exchanged for buffer containing BoNT.
Muscle activity was recorded until no further muscle contraction was detected. The potency of BoNTs was estimated as: the time to reduce the amplitude of diaphragm contraction to 50% (t 50 ) of control following BoNT addition. Following complete paralysis, the mus- All BoNTs and the vehicle (GPB) were administered at 20 μL/animal volume in mice and 10 μL/animal volume in rats. The injections were performed using a 30-gauge needle attached to a 100 μL syringe. At the end of the experiment, or earlier if deemed necessary, animals were culled by CO 2 asphyxiation.
| DAS tests in mice and rats
The mouse DAS test was performed as previously described. 17 Mice were suspended briefly by the tail to elicit a typical startle response characterized by the hind limb extension and abduction of digits. The mouse DAS was assessed using a five-point scale: DAS 0 = normal to DAS 4 = maximal reduction in digit abduction and leg extension.
Mice were scored for DAS response at baseline (day 0) and daily on 
| BW change in response to BoNT treatment in mice and rats
In mice, BWs were monitored daily for four days and the percentage of BW change from day 0 (% BW) was calculated for each dose. As each serotype resulted in BW loss at high doses, a linear regression analysis was used to calculate a theoretical dose for which there was no weight gain (0% BW) when compared with day 0 for each serotype. The tolerability index for each serotype in mice was calculated as 0% BW/ED 50 .
In rats, BWs were monitored daily for 15 days. As overall no BW loss was detected in any treated groups (see Results below), effects of BoNT serotypes on BW gain in the rat was assessed by calculating the difference in percent change in BW from day 0 (% BW) between BoNT-treated vs vehicle-treated groups.
| Data and statistical analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology. 24 value calculated per serotype). In vivo BW data (see Tables S1 and   S2 ) were analyzed by one-way ANOVA followed by Dunnett's post hoc analysis (JMP 13.1.0., SAS Institute Inc). Statistical significance was established at P < 0.05 throughout the manuscript.
| RESULTS
| SNARE cleavage in rat in vitro assays
BoNT serotypes A to F produced a concentration-dependent increase in SNARE cleavage in the three rat in vitro assays tested (see Figure 1 and Table 1 ). The maximal SNARE cleavage (~100% of the corresponding target SNARE protein) was seen at the highest DONALD ET AL. Table 1 ). For serotype B, there was a 35-fold difference in its Table 1 being the less preferred target. For serotype C, SNAP-25 cleavage was roughly equivalent (up to fourfold higher) to syntaxin cleavage in the three models (4-, 0.7-, and 1.5-fold for SCN, DRG, and CTX, respectively).
| Neurotransmitter release in rat in vitro assays
BoNT serotypes A to F produced a concentration-dependent decrease in the release of glycine in SCN and in the release of glutamate in CTX following BoNT intoxication ( Figure 2 and Table 2 ). The rank order of potency in the SCN glycine release assay was A >B > C = D > E > F. The rank order of potency in the CTX glutamate release assay was A > D = C = E > F = B.
In both release assays serotype A showed a residual release of 20% at the bottom asymptote for the assay, corresponding to the maximal concentrations tested (Figure 2 ). In the SCN glycine release assay, a high residual neurotransmitter release was seen for serotypes A, B, D, and F (21.72 ± 2.27% n = 8 for A, 16.79 ± 0.94% n = 7 for B, 15.92 ± 1.12% n = 5 for D, and 13.20 ± 1.27% n = 7
for F, mean ± SEM n experiments run in triplicate), whereas the inhibition of release was complete within margins of error for serotypes E and C (5%-6% range for both). There were statistical differences for serotypes C and E in comparison to A (P < 0.05). In the CTX assay, only serotype A showed a high residual neurotransmitter release (24.85 ± 2.36%, mean ± SEM n = 5 experiments run in triplicate), whereas other serotypes were statistically different and close to complete inhibition of glutamate release (between 2.6 and 6% for serotypes B, C, D, E, and F).
| Mouse PNHD assay
BoNT serotypes A to F produced a concentration-dependent decrease in the muscle contractility of mouse PNHD ( Figure 3A , Table 3 and Table S3 ). At 10 pmol/L all serotypes produced complete inhibition of contractile force between 70 and 400 minutes (data not shown). The rank order of potency, using a calculated concentration that would produce a half-paralytic time of 70 minutes for all toxins,
| Potency and tolerability in the mouse DAS test
In mice, acute, i.m. administration of BoNT serotypes A, B, C, E, and Table 4 ). For serotype D, no doserelated effects on DAS were seen, and DAS 2 value was not reached at doses up to 45 pg/animal, whereas lethality was detected at 80 pg/animal. Thus, the rank order of BoNT potency in mice was B, A, C, F, E; with D not being determined and considered the least potent serotype.
Acute, i.m. administration of BoNT serotypes also resulted in dose-related changes in BW in mice, including BW loss at higher doses (Table S1 ). The calculated doses associated with no change in BW (0% BW) ranged from 2.8 (for serotype B) to 41.9 pg/animal (for serotype F, Table 4 ). The rank order of tolerability index, calculated as 0% BW/ED 50 was B, A, F, C, E, in which serotype B had the largest tolerability index and serotype E, the smallest. Lethality was observed in animals treated at 80 pg/animal of serotype D (without inducing DAS 2) and those treated at 45 pg/animal of serotype C (while inducing DAS 4). Therefore, serotype C is considered the most toxic serotype in CD-1 mice.
| Potency and tolerability in the rat DAS test
In rats, acute, i.m. administration of BoNT serotypes A, B, C, E and F resulted in dose-related increases in DAS values, the maximal score of DAS 4 being reached 1 to 3 days postadministration (Fig. S2) . The Data are mean ± SEM of n = 5-8 independent experiments (n numbers indicated in Table) Table 5 ). The ED 50 values were not determined for serotype D, since DAS 4 was not reached. Thus, the rank order of BoNT potency in rats was A, C, F, E, B.
At the dose range tested, none of these serotypes showed any effect on BW gain (Table S2) . A transient effect of 6500 pg/animal of serotype B on BW gain was seen, but lacked dose-dependency (data not shown). Data are mean ± SEM of n = 5-8 independent experiments (n numbers indicated in Table) performed in triplicate. BoNT, Botulinum neurotoxinsl; CTX, cerebral cortical neurons cell culture One-way ANOVA followed by Bonferroni's post hoc test revealed statistical significance as follows: *P < 0.05 vs A, † P < 0.05 vs B, ‡ P < 0.05 vs C, § P < 0.05 vs D, and ¶ P < 0.05 vs E.
| Correlation between in vitro, ex vivo, and in vivo data
(P < 0.05). This significance was also retained when B VAMP1 SNARE cleavage data were used (r = 0.933, P = 0.006*, n = 6 XY pairs)
instead of B VAMP2 values (data depicted in Table 6 ).
Serotype E appeared to be an outlier when the mouse PNHD was compared to the mouse DAS ( Figure 4A ) and, if this serotype was excluded from the analysis, a correlation was observed (r = 0.966, P = 0.034*, n = 4 XY pairs).
| DISCUSSION
This study provides for the first time comprehensive profiles of the purified native, commercially available and research grade BoNT serotypes A1 to F1 in rodent in vitro, ex vivo, and in vivo assays.
Here, BoNT serotype A1, the most potent serotype in the clinic, was also the most potent serotype in all rodent assays tested here, except for the mouse DAS test in which serotype B1 appeared to be the most potent. The potency rankings of serotypes across the in vitro assays are in broad agreement with previously reported data in SCN (A>C~E>B; 26 ), DRG (A>C>F>B) 15 , and CTX (A∼C>E>B>F). 27 The high potency of A in comparison to other serotypes has been also confirmed ex vivo and in vivo, such as when assessing A and B in the mouse PNHD, 22, 28 A, B, and E in the mouse PNHD, 29 A, B, C, and F in the mouse DAS, 18 and serotypes A to F in the rat compound muscle action potential (CMAP) 30 . Interestingly, there are some exceptions to A being the most potent serotype in both mammalian and nonmammalian species. 31, 32 BoNT serotype B, the only alternative to A used currently in the clinic, displays lower efficacy in humans due to a mutation in the synaptotagmin 2 receptor which results in its poor affinity at this receptor. 33 Here, B1 was highly potent in mice both in the PNHD and in vivo models, consistent with previously reported data for this species in in vitro and ex vivo assays. 34 In rats, B1 was the least potent serotype in vivo as well as in the SCN assay when evaluating VAMP1 cleavage, in agreement with reports of VAMP1 being relatively resistant to cleavage by serotype B 35 and the role of VAMP1 at neuromuscular junctions. 34 BoNT serotypes C, E, and F have been used in humans in a small number of case studies. 36 Serotype C has a temporal profile similar
to that of A and shows a positive clinical outcome in patients. 36 Here, serotype C1 was the second most potent serotype in DRG, only surpassed by A1. The high potency in the sensory model DRG could make C1 a potential starting point to develop a BoNT-based therapeutic aimed at sensory conditions. However, in this study C1 shows concentration response curves in the digit abduction score (DAS) test in mice, and (C) shows concentration response curves in the DAS test in rats. Mouse PNHD data are mean ± SEM from n = 5-20 independent experiments per concentration (see Table 3 for details). For DAS data each point represents the observed mean from individual experiments with n = 6 animals per dose. See Tables 3-5 , for further details; DAS, Digit Abduction Score; PNHD, phrenic nerve hemidiaphragm; PNHD: phrenic nerve hemidiaphragm assay was the most lethal serotype in the in vivo mouse assay. Neurotoxicity of serotype C1 has been linked to the ability to cleave two independent SNARE proteins, SNAP-25 and syntaxin. 37 Interestingly, cleavage activity and lethality of serotype C1 can be modulated using recombinant techniques. Cleavage of SNAP-25 by serotype C1
has been linked to its lethality, whereas its cleavage of syntaxin would be responsible for its induced neuromuscular paralysis. 38 Here, the potency of serotype C1 at cleaving SNAP-25 and syntaxin was almost equivalent in SCN, CTX, and DRG confirming previous reports using rat hippocampal neurons. 39 In this study, serotype C1
was the second most potent serotype in rat DAS, measuring muscle relaxation, only surpassed by A. This is well-aligned with the activity of serotype C in the rat CMAP analysis in vivo. 30 Also, serotype C was found as potent as A in the DAS test performed in Swiss Webster mice. 18 In humans, BoNT serotypes E and F both are associated with a shorter duration of action when compared to A. 36, 40 Therefore, we can speculate that these two serotypes might be useful in the clinic where a short blockade is required, for example, to immobilize damaged joints in pre and postoperative care. Serotype F1 was~three-fold more potent than B1 and E1 in the DRG sensory model, but it was the least potent serotype in SCN and CTX. F1 also showed moderate potency in mouse PNHD, mouse DAS, and rat DAS, suggesting it could be a potential serotype, with differentiating properties over A1, to favor sensory over motor conditions. In our study, serotype E1 was as potent as A1 in the mouse PNHD, as similarly reported by Rasetti-Escargueil et al. 29 In the mouse DAS test, serotypes E1 and F1 were among the least potent serotypes, while
showing intermediate potency in the rat DAS test. The intermediate potency of E and F is also reported in a rat CMAP study. 30 In our rat DAS study, no serotype had any effect on BW at the dose range tested. As effects on BW are thought to indicate systemic spread of neurotoxin into systemic circulation, we can conclude that in these studies all serotypes were well-tolerated in the Table S3 for individual data points). Z-test analysis followed by Sidak's correction revealed the rank order of potency as follows: A = B > E > F = C = D. BoNT, Botulinum neurotoxins; PNHD, phrenic nerve hemidiaphragm. Four to ten groups of n = 6 animals each were treated with increasing doses of BoNT for each serotype. For details and data calculations please refer to material and methods and Figure S1 . ND, not determined; BoNT, Botulinum neurotoxins. Five to ten groups of n = 6 animals each were treated with increasing doses of BoNT for each serotype. For details and data calculations please refer to Material and Methods and Figure S2 . ND, not determined; BoNT, Botulinum neurotoxins; BW, body weight. showing low potency. The results for serotype D1 are in contrast to previous reports using recombinant or native BoNT/D. 25, 42 The lower potency of serotype D1 found here by that study may be due to differences in purity (<50% purity in this study), toxin, toxin manufacture, or experimental conditions. All serotypes, with the excep- 
| CONCLUSION
The native BoNT serotypes A1 to F1 are highly potent neurotoxins in rodent assays, except for serotype D1 in vivo in mice and rats.
Rat models were found to be not suitable to study the potency of serotype B1.
Potency differences of BoNT serotypes in tissues and species can be exploited to develop unique novel BoNT-based therapeutics.
In particular, serotypes F1 and C1 could be the base of new botulinum products aimed at the somatosensory system.
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